ResMed (RMD) Stock Forecast & Price Target

Q: What analysts cover ResMed?

ResMed has been rated by research analysts at Citigroup , KeyCorp , Mizuho , Piper Sandler , Robert W. Baird , Rothschild & Co Redburn , Royal Bank Of Canada , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$229.97 +3.24 (+1.43%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$230.08 +0.11 (+0.05%)

As of 10/9/2026 07:30 PM Eastern

Compare

ResMed - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 16 Analyst Ratings

Sell
0

Hold
9

Buy
7

Based on 16 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 9 have given a hold rating, and 7 have given a buy rating for RMD.

Consensus Price Target

$241.69
5.10% Upside

According to the 16 analysts' twelve-month price targets for ResMed, the average price target is $241.69. The highest price target for RMD is $300.00, while the lowest price target for RMD is $213.00. The average price target represents a forecasted upside of 5.10% from the current price of $229.97.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RMD Analyst Ratings Over Time

Type	Current Forecast 10/10/25 to 10/10/26	1 Month Ago 9/10/25 to 9/10/26	3 Months Ago 7/12/25 to 7/12/26	1 Year Ago 10/10/24 to 10/10/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)	10 Buy rating(s)
Hold	9 Hold rating(s)	10 Hold rating(s)	8 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$241.69	$240.31	$260.17	$294.20
Forecasted Upside	5.10% Upside	9.33% Upside	27.43% Upside	8.18% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Healthcare Companies	Broader Market
Consensus Rating Score	2.44	2.32	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	5.10% Upside	927.18% Upside	19.50% Upside
News Sentiment Rating	Positive News See Recent RMD News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/8/2026	Weiss Ratings 3 of 5 stars		Upgrade	Hold (C) ➝ Hold (C+)
9/15/2026	Royal Bank Of Canada 3 of 5 stars	Craig Wong-Pan Not Rated	Upgrade	Sector Perform ➝ Outperform	$244.00 ➝ $262.00	+17.46%
9/10/2026	Citigroup 4 of 5 stars	Laura Sutcliffe Not Rated	Reiterated Rating	Neutral
8/31/2026	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brett Fishbin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$255.00 ➝ $267.00	+11.03%
8/19/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jackson Philips Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral	$230.00	+4.42%
8/7/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$213.00	-1.07%
8/7/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$233.00 ➝ $225.00	+7.36%
8/7/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nathan Treybeck Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$225.00 ➝ $215.00	+1.80%
7/21/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$300.00	+53.10%
7/15/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$235.00 ➝ $220.00	+12.30%
Get the Latest News and Ratings for RMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.
7/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$240.00 ➝ $225.00	+9.78%
7/1/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
6/17/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Bailey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$286.00 ➝ $230.00	+18.48%
4/15/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Low Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight
4/13/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform	$255.00	+11.52%
1/30/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$260.00 ➝ $265.00	+2.78%
9/2/2025	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Outperform
8/1/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
1/31/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:42 AM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 6, 2026. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

ResMed Inc. recently reported strong financial performance for the quarter ended August 6, 2026, with earnings per share of $2.95, which exceeded the consensus estimate of $2.89, and revenue of $1.46 billion that grew 8.6% year-over-year, demonstrating robust demand for its sleep and respiratory care products.
The company has a solid balance sheet with a low debt-to-equity ratio of 0.06 and a current ratio of 3.10, indicating strong liquidity and financial stability that can support long-term growth and shareholder returns without significant financial risk.
ResMed Inc. recently increased its quarterly dividend from $0.60 to $0.66, resulting in an annualized dividend yield of approximately 1.2%, which provides a steady income stream for investors and signals management confidence in the company's cash flow generation.
Analysts have recently upgraded their outlook on the stock, with Royal Bank of Canada raising its rating to "outperform" and KeyCorp increasing its price target to $267.00, reflecting positive sentiment about the company's growth potential in the sleep apnea and respiratory care markets.
The stock is currently trading at $221.02, which is below the consensus price target of $241.69, suggesting potential upside for investors who believe in the company's long-term growth strategy and market position.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

ResMed Inc. has a consensus rating of "Hold" from sixteen ratings firms, with nine analysts assigning a hold rating and seven assigning a buy rating, indicating a lack of strong consensus for significant near-term price appreciation.
Short interest in the stock has been increasing, with 14,203,907 shares shorted as of September 15, 2026, representing approximately 9.9% of the float, which suggests that a significant portion of investors are betting against the stock's price movement.
Insider selling has been consistent, with CEO Michael J. Farrell and Director Peter C. Farrell both selling shares in recent months, which may indicate that company insiders are taking advantage of current valuations to reduce their personal holdings.
The stock has experienced volatility, including a gap down of 16.06% on August 7, 2026, and a 52-week low of $180.26, which may deter risk-averse investors who prefer more stable price movements.
ResMed Inc. faces rising competitive pressures in the sleep apnea and respiratory care markets, which could impact its market share and profitability if it fails to maintain its technological and product leadership.

RMD Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $241.69, with a high forecast of $300.00 and a low forecast of $213.00.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 9 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.

According to analysts, ResMed's stock has a predicted upside of 5.10% based on their 12-month stock forecasts.

Over the previous 90 days, ResMed's stock had 3 upgrades and 3 downgrades by analysts.

ResMed has been rated by research analysts at Citigroup, KeyCorp, Mizuho, Piper Sandler, Robert W. Baird, Rothschild & Co Redburn, Royal Bank Of Canada, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like ResMed more than other "healthcare" companies. The consensus rating score for ResMed is 2.44 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With ResMed Recommendations

MarketBeat monitors more than a dozen sources for ResMed analyst ratings, with the most recent rating issued on 10/8/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target